Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Applied Drug Research, Clinical Trials and Regulatory Affairs
  4. Volume 10, Issue 1
  5. Article
Volume 10, Issue 1
  • ISSN: 2667-3371
  • E-ISSN: 2667-338X

Abstract

This article presents a comprehensive and comparative analysis of the regulatory frameworks governing the approval of pharmaceuticals in the Dominican Republic, Ecuador, and Nicaragua. It delves into the intricate scientific terminology and complex procedures inherent in these regulatory systems, shedding light on the demanding requirements that pharmaceutical companies must fulfil to secure market access in these countries. Employing a comparative approach, the article explores both the analogy and differences in the approval processes, focusing on factors such as safety standards, efficacy assessments, clinical trial prerequisites, post-marketing surveillance, and overall transparency. The findings contribute to a deeper understanding of the scientific accuracy and ongoing efforts towards regulatory harmonisation within the pharmaceutical industry across these countries. Furthermore, this study aims to define the regulatory requirements for drug approval in the LATAM region, explicitly emphasising the Dominican Republic, Ecuador, and Nicaragua. It provides insights into the current pharmaceutical market landscape in Latin America, compares the regulatory requirements for drug approval in these three countries, and offers guidance on preparing dossiers for obtaining authorisation of pharmaceutical drug products. By examining the similarities and differences in regulatory standards, this article facilitates a comprehensive understanding of the stringency ratios between these countries and assists companies in navigating the specific regulatory landscapes to achieve successful drug approvals.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/adctra/10.2174/0126673371287527240502114352
2024-05-23
2024-11-22

  • From This Site

    /content/journals/adctra/10.2174/0126673371287527240502114352
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. AlejandroCFD Latin America in the 1930s.Modern Political Economy And Latin America.United Kingdom: RoutledgeLondon2018140151
     [Google Scholar]
  2. SingamS.L.S.R. YetukuriK. NadendlaR.R. Drug registration requirements for pharmaceuticals in emerging markets.Int J Drug Reg Affairs202084738210.22270/ijdra.v8i4.442
     [Google Scholar]
  3. Ramírez-TellesM. Argotti-RodríguezU. Regulation of drug prescribing information in Latin America and the Caribbean.Ther. Innov. Regul. Sci.202256453655110.1007/s43441‑022‑00396‑y35380375
     [Google Scholar]
  4. StatistaPharmaceutical imports and exports of major Latin American countries in 2022.2022Available From: https://www.statista.com/statistics/418042/pharma-imports-and-exports-in-latin-america-by-major-country/
  5. PratA.G. A practical overview of requirements for drug registration in Latin America.Reg Rapporteur2013109510
     [Google Scholar]
  6. LemkeC. Supporting the value proposition of the pharmaceutical industry in Mexico.2016Available From: https://www.wifor.com/uploads/2019/02/WifOR_AMIIF_Value_Proposition_of_Pharma_Industry_in_Mexico-1.pdf
    [Google Scholar]
  7. SravaniM. KusumaM. PrabhaharA. NadendlaR. Registration of generic drugs in Central America and Mexico.Int J Pharma Chem Res201733635650
     [Google Scholar]
  8. ReddyM. Latin American Pharmaceutical Regulatory environment–review article.Int Res Pharm Nano Sci20143122131
     [Google Scholar]
  9. Pilamala RosalesA. LinnemannA.R. LuningP.A. A Net-Map analysis to understand the roles and influence of stakeholders in street food safety - A study in Ecuador.Food Control202315410996610.1016/j.foodcont.2023.109966
     [Google Scholar]
  10. WDAPharmaceutical products registration in dominican republic.2023Available From: https://wdalaw.com/publications/articles/natural-productsregistration-in-dominican-republic.php
    [Google Scholar]
  11. Orozco-SolaresT.E. León-MorenoL.C. Rojas-RizoA. Manguart-PáezK. CaplanA.I. Allogeneic mesenchymal stem cell-based treatment legislation in Latin America: The need for standardization in a medical tourism context.Stem Cells Dev.2022317-814316210.1089/scd.2022.001335216516
     [Google Scholar]
  12. VásquezAGT Risk based approach of post-approval changes in central America and Dominican republic, identifying opportunities for convergence with EMA and FDA.2021
     [Google Scholar]
  13. BendañaP.B. Requirements for pharmaceutical regulatory affairs in Nicaragua.2019Available From: https://pharmaboardroom.com/legal-articles/requirements-forpharmaceutical-regulatory-affairs-in-nicaragua/
    [Google Scholar]
  14. Ortiz-PradoE. Health status and medication consumption in Ecuador.2015Available From: https://www.researchgate.net/publication/292610565_HEALTH_STATUS_AND_MEDICATION_CONSUMPTION_IN_ECUADOR
    [Google Scholar]
  15. Wilbert BannenbergV.K. Regional assessment of drug registration and regulatory systems in CARICOM member states and the dominican republic.CARICOM Regional Assess Drug Reg Regul Syst2009I61
     [Google Scholar]
  16. TejeraE. SánchezM.E. Henríquez-TrujilloA.R. Pérez-CastilloY. Coral-AlmeidaM. A population-based study of preeclampsia and eclampsia in Ecuador: Ethnic, geographical and altitudes differences.BMC Preg Childbirth202121111610.1186/s12884‑021‑03602‑133563238
     [Google Scholar]
  17. DuránC. Regulation, consumption and expenditures of new cancer drugs in Ecuador and Latin America2021
     [Google Scholar]
  18. Rayuela RadioS.D. De La JudicaturaC. Access to Drugs and the Situation of the Pharmaceutical Market in Ecuador.2020Available From: https://www.fisd.in/sites/default/files/Publication/ITEC%20Report%20on%20Science%20Diplomacy%202020_Webmin%20%281%29.pdf
    [Google Scholar]
  19. De PaepeP. TapiaR.E. SantacruzE.A. UngerJ.P. Ecuador’s silent health reform.Int. J. Health Serv.201242221923310.2190/HS.42.2.e22611652
     [Google Scholar]
  20. Legal-Team-EcuadorProduct registration in Ecuador Can be Straightforward.2021Available From: https://www.bizlatinhub.com/product-registration-ecuador/
    [Google Scholar]
  21. PetrickH.J. Song text and song structure: With an emphasis on oral/aural tradition.2023Available From: https://digitalcommons.liberty.edu/cgi/viewcontent.cgi?article=1995&context=masters
    [Google Scholar]
  22. Liz LirianoH. El gas natural como una fuente potencial para el desarrollo energético sostenible en la República Dominicana: Una revisión.Ciencia Ambiente y Clima2022513952
     [Google Scholar]
  23. KeysH.M. KaiserB.N. FosterJ.W. Cholera control and anti-Haitian stigma in the Dominican Republic: From migration policy to lived experience.Anthropol. Med.201926212314110.1080/13648470.2017.136882929058456
     [Google Scholar]
  24. World Health OrganizationPharmaceuticals in the Americas.1995
     [Google Scholar]
  25. YoungersC. RosinE. Drugs and democracy in Latin America: The impact of US policy.Boulder, ColoradoLynne Rienner Pub2005
     [Google Scholar]
  26. ChapmanH.J. Veras-EstévezB.A. PomeranzJ.L. Pérez-ThenE.N. MarcelinoB. LauzardoM. Perceived barriers to adherence to tuberculosis infection control measures among health care workers in the Dominican Republic.MEDICC Rev.2017191162210.37757/MR2017.V19.N1.428225541
     [Google Scholar]
  27. SadlerK. WilsonK. Dominican Republic: A guide for global health workers, medical practitioners, and NGO volunteers.ChicagoDartmouth College Press201571
     [Google Scholar]
  28. KelleherS.P. ReyesD. Technical measures to trade in Central America: Incidence, price effects, and consumer welfare.2014Available From: https://ideas.repec.org/p/wbk/wbrwps/6857.html
    [Google Scholar]
  29. WDAWDA LAW.2024Available From: https://wdalaw.com/about-wda.php
    [Google Scholar]
  30. U.S. Department of StateThe Dominican Republic. In:2018Available From: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K190334
  31. LausanneRd. Pharmaceuticals, cosmetics, personal hygiene products and domestic hygiene products.2023Available From: https://importlicensing.wto.org/content/pharmaceuticals-cosmeticspersonal-hygiene-products-and-domestic-hygiene-products-0
    [Google Scholar]
  32. LogisticsClustetr 1.2 Dominican republic regulatory departments and quality control.2022Available From: https://dlca.logcluster.org/12-dominican-republic-regulatorydepartments-and-quality-control
    [Google Scholar]
  33. WHOGuidelines for diagnosing and managing disseminated histoplasmosis among people living with HIV.2020Available From: https://www.who.int/publications/i/item/9789240006430
    [Google Scholar]
  34. BledelE.E. Food regulation in Latin America.Food Drug Cosmet. Law J.1973289585595
     [Google Scholar]
  35. Sanitary registration in Nicaragua.2017Available From: https://alvaradoyasociadoslegal.com/english-blog/sanitary-registration-in-nicaragua/
  36. Taft-MoralesM. Nicaragua: In brief.2016Available From: https://sgp.fas.org/crs/row/R44560.pdf
    [Google Scholar]
  37. DuránC.E. CañásM. UrtasunM.A. Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries.Rev. Panam. Salud Publica20214511010.26633/RPSP.2021.1033859678
     [Google Scholar]
  38. PatelP. BadjatyaJ.K. HingeM. Comparative study of regulatory requirements of Drug Product in Emerging market.Int J Drug Regul Aff201973486210.22270/ijdra.v7i3.350
     [Google Scholar]
  39. HomedesN. López LinaresR. UgaldeA. Generic drug policies in Latin America.2005Available From: https://documents.worldbank.org/en/publication/documentsreports/documentdetail/945221468269681466/generic-drug-policies-in-latin-america
    [Google Scholar]
  40. Sanitary registration2018Available From: https://proassem.com/en/sanitary-registration/
  41. BastianS. Drug regulation in Latin America: A guide for small business.2012Available From: http://consulting-forpharma.com/fileadmin/user_upload/documents/RA_in_LATAM_cfp.pdf
    [Google Scholar]
  42. PharmaBoardroomMarketing, manufacturing, packaging & labelling, advertising.2018Available From: https://pharmaboardroom.com/legal-articles/marketingmanufacturing-packaging-labelling-india/
    [Google Scholar]
  43. BadjatyaJ.K. Overview of drug registration requirements for pharmaceuticals in emerging market.J. Drug Deliv. Ther.20133210.22270/jddt.v3i2.466
     [Google Scholar]
  44. MohitDeep A KhuranaG. KumarJ. MongaA. Comparison of basic regulatory requirements for generic drug products registration in CIS and Latin American Countries.Appl. Clin. Res. Clin. Trials Regul. Aff.20207211712510.2174/2213476X06666191023093840
     [Google Scholar]
  45. JakovljevicM. CerdaA.A. LiuY. Sustainability challenge of Eastern Europe—historical legacy, belt and road initiative, population aging and migration.Sustainability (Basel)202113191103810.3390/su131911038
     [Google Scholar]
  46. SchellekensR. SmithJ. Synthesis of Multifunctional Hybrid Semiconductor NanomaterialsMultifunctional Hybrid Semiconductor Photocatalyst Nanomaterials.Berlin, HeidelbergSpringer2023315110.1007/978‑3‑031‑20298‑8_35
     [Google Scholar]
  47. VoglerS. Prices of new medicines: International analysis and policy options.Z. Evid. Fortbild. Qual. Gesundhwes.20221759610210.1016/j.zefq.2022.09.00936372642
     [Google Scholar]
  48. NwokikeJ. Regulatory reliance and post-marketing surveillance systems for safe and accelerated introduction of new medical products in low-and middle-income countries2023
     [Google Scholar]
  49. PucikV. EvansP. BjorkmanI. JhaveriK. The global challenge: International human resource management.Thousand Oaks, CaliforniaSAGE Publications2016
     [Google Scholar]
  50. KohtamäkiM. RabetinoR. EinolaS. ParidaV. PatelP. Unfolding the digital servitization path from products to product-service-software systems: Practicing change through intentional narratives.J. Bus. Res.202113737939210.1016/j.jbusres.2021.08.027
     [Google Scholar]
  51. ShahS. NeneS. RangarajN. RaghuvanshiR.S. SinghS.B. SrivastavaS. Bridging the gap: Academia, industry and FDA convergence for nanomaterials.Drug Dev. Ind. Pharm.202046111735174610.1080/03639045.2020.182105532901536
     [Google Scholar]
  52. PetersK. A comparative overview of the regulatory landscapes around real-world data/real-world evidence in the USA and the EU, and the wider perspective.2022Available From: https://www.dgra.de/media/pdf/studium/masterthesis/master_peters_karla_2022.pdf
    [Google Scholar]
  53. RiveraV.M. MaciasM.A. Access and barriers to MS care in Latin America.Mult. Scler. J. Exp. Transl. Clin.20173110.1177/205521731770066828607755
     [Google Scholar]
/content/journals/adctra/10.2174/0126673371287527240502114352
Loading
Pharmaceutical Market Access in Latin America: Analyzing Approval Requirements in Three Key Nations: Ecuador, Dominican Republic and Nicaragua
Applied Drug Research, Clinical Trials and Regulatory Affairs 10, E230524230257 (2024); https://doi.org/10.2174/0126673371287527240502114352
/content/journals/adctra/10.2174/0126673371287527240502114352
/content/journals/adctra/10.2174/0126673371287527240502114352
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Legal frame work; life sciences; lucrative market; pharmaceutical drug; scientific accuracy; trade deficit

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test